The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IWWM-12 2024 | Unmet needs in WM: managing high-risk disease, sequencing novel agents, & personalizing treatment
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the unmet needs in treating Waldenström’s macroglobulinemia (WM), particularly in managing high-risk patients and optimizing the sequencing of novel therapies. He highlights the contributions of young investigators, especially their genomic findings, which are paving the way for more individualized approaches. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
